Combination Treatment with Hepatitis C Virus Protease and NS5A Inhibitors is Effective Against Recombinant Genotype 1a, 2a, and 3a Viruses

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2013 Jan 1

PMID 23274664

Citations 21

Authors

Judith M Gottwein

Sanne B Jensen

Yi-Ping Li

Lubna Ghanem

Troels K H Scheel

Stephanie B N Serre

Lotte Mikkelsen

Jens Bukh

Affiliations

Soon will be listed here.

Abstract

With the development of directly acting antivirals, hepatitis C virus (HCV) therapy entered a new era. However, rapid selection of resistance mutations necessitates combination therapy. To study combination therapy in infectious culture systems, we aimed at developing HCV semi-full-length (semi-FL) recombinants relying only on the JFH1 NS3 helicase, NS5B, and the 3' untranslated region. With identified adaptive mutations, semi-FL recombinants of genotypes(isolates) 1a(TN) and 3a(S52) produced supernatant infectivity titers of ~4 log(10) focus-forming units/ml in Huh7.5 cells. Genotype 1a(TN) adaptive mutations allowed generation of 1a(H77) semi-FL virus. Concentration-response profiles revealed the higher efficacy of the NS3 protease inhibitor asunaprevir (BMS-650032) and the NS5A inhibitor daclatasvir (BMS-790052) against 1a(TN and H77) than 3a(S52) viruses. Asunaprevir had intermediate efficacy against previously developed 2a recombinants J6/JFH1 and J6cc. Daclatasvir had intermediate efficacy against J6/JFH1, while low sensitivity was confirmed against J6cc. Using a cross-titration scheme, infected cultures were treated until viral escape or on-treatment virologic suppression occurred. Compared to single-drug treatment, combination treatment with relatively low concentrations of asunaprevir and daclatasvir suppressed infection with all five recombinants. Escaped viruses primarily had substitutions at amino acids in the NS3 protease and NS5A domain I reported to be genotype 1 resistance mutations. Inhibitors showed synergism at drug concentrations reported in vivo. In summary, semi-FL HCV recombinants, including the most advanced reported genotype 3a infectious culture system, permitted genotype-specific analysis of combination treatment in the context of the complete viral life cycle. Despite differential sensitivity to lead compound NS3 protease and NS5A inhibitors, genotype 1a, 2a, and 3a viruses were suppressed by combination treatment with relatively low concentrations.

Citing Articles

Full-length sequence analysis of hepatitis C virus genotype 3b strains and development of an infectious 3b cDNA clone.

Bajpai P, Collignon L, Solund C, Madsen L, Christensen P, Ovrehus A J Virol. 2023; 97(12):e0092523.

PMID: 38092564 PMC: 10734419. DOI: 10.1128/jvi.00925-23.

In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?.

Echeverria N, Comas V, Aldunate F, Perbolianachis P, Moreno P, Cristina J World J Hepatol. 2021; 13(10):1234-1268.

PMID: 34786164 PMC: 8568586. DOI: 10.4254/wjh.v13.i10.1234.

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 .

Gammeltoft K, Zhou Y, Duarte Hernandez C, Galli A, Offersgaard A, Costa R Antimicrob Agents Chemother. 2021; 65(9):e0268020.

PMID: 34097489 PMC: 8370243. DOI: 10.1128/AAC.02680-20.

Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.

Ramirez S, Fernandez-Antunez C, Mikkelsen L, Pedersen J, Li Y, Bukh J Antimicrob Agents Chemother. 2019; 64(3).

PMID: 31818814 PMC: 7038289. DOI: 10.1128/AAC.01888-19.

Development of an Infectious Cell Culture System for Hepatitis C Virus Genotype 6a Clinical Isolate Using a Novel Strategy and Its Sensitivity to Direct-Acting Antivirals.

Chen M, Zheng F, Yuan G, Duan X, Rong L, Liu J Front Microbiol. 2018; 9:2950.

PMID: 30564209 PMC: 6288186. DOI: 10.3389/fmicb.2018.02950.

References

Sarrazin C, Hezode C, Zeuzem S, Pawlotsky J . Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012; 56 Suppl 1:S88-100. DOI: 10.1016/S0168-8278(12)60010-5. View

Gottwein J, Scheel T, Jensen T, Ghanem L, Bukh J . Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology. 2011; 141(3):1067-79. DOI: 10.1053/j.gastro.2011.06.004. View

Yanagi M, Purcell R, Emerson S, Bukh J . Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A. 1997; 94(16):8738-43. PMC: 23104. DOI: 10.1073/pnas.94.16.8738. View

Shimakami T, Welsch C, Yamane D, McGivern D, Yi M, Zeuzem S . Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology. 2010; 140(2):667-75. PMC: 3155954. DOI: 10.1053/j.gastro.2010.10.056. View

Tong X, Guo Z, Wright-Minogue J, Xia E, Prongay A, Madison V . Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry. 2006; 45(5):1353-61. DOI: 10.1021/bi051565g. View

Lohmann V, KORNER F, Koch J, Herian U, Theilmann L, Bartenschlager R . Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999; 285(5424):110-3. DOI: 10.1126/science.285.5424.110. View

Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S . Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005; 42(4):962-73. DOI: 10.1002/hep.20819. View

Thibeault D, Bousquet C, Gingras R, Lagace L, Maurice R, White P . Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J Virol. 2004; 78(14):7352-9. PMC: 434094. DOI: 10.1128/JVI.78.14.7352-7359.2004. View

Murayama A, Kato T, Akazawa D, Sugiyama N, Date T, Masaki T . Production of infectious chimeric hepatitis C virus genotype 2b harboring minimal regions of JFH-1. J Virol. 2011; 86(4):2143-52. PMC: 3302416. DOI: 10.1128/JVI.05386-11. View

10.

McPhee F, Friborg J, Levine S, Chen C, Falk P, Yu F . Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother. 2012; 56(7):3670-81. PMC: 3393445. DOI: 10.1128/AAC.00308-12. View

11.

Li Y, Ramirez S, Gottwein J, Scheel T, Mikkelsen L, Purcell R . Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proc Natl Acad Sci U S A. 2012; 109(18):E1101-10. PMC: 3344947. DOI: 10.1073/pnas.1203829109. View

12.

Li Y, Gottwein J, Scheel T, Jensen T, Bukh J . MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. Proc Natl Acad Sci U S A. 2011; 108(12):4991-6. PMC: 3064388. DOI: 10.1073/pnas.1016606108. View

13.

Pietschmann T, Zayas M, Meuleman P, Long G, Appel N, Koutsoudakis G . Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog. 2009; 5(6):e1000475. PMC: 2691593. DOI: 10.1371/journal.ppat.1000475. View

14.

Wang C, Huang H, Valera L, Sun J, OBoyle 2nd D, Nower P . Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother. 2012; 56(3):1350-8. PMC: 3294925. DOI: 10.1128/AAC.05977-11. View

15.

Gao M, Nettles R, Belema M, Snyder L, Nguyen V, Fridell R . Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010; 465(7294):96-100. PMC: 7094952. DOI: 10.1038/nature08960. View

16.

Gottwein J, Scheel T, Hoegh A, Lademann J, Eugen-Olsen J, Lisby G . Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology. 2007; 133(5):1614-26. DOI: 10.1053/j.gastro.2007.08.005. View

17.

Bukh J, Pietschmann T, Lohmann V, Krieger N, Faulk K, Engle R . Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci U S A. 2002; 99(22):14416-21. PMC: 137898. DOI: 10.1073/pnas.212532699. View

18.

Summa V, Ludmerer S, McCauley J, Fandozzi C, Burlein C, Claudio G . MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012; 56(8):4161-7. PMC: 3421554. DOI: 10.1128/AAC.00324-12. View

19.

Lok A, Gardiner D, Lawitz E, Martorell C, Everson G, Ghalib R . Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012; 366(3):216-24. DOI: 10.1056/NEJMoa1104430. View

20.

Scheel T, Gottwein J, Mikkelsen L, Jensen T, Bukh J . Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Gastroenterology. 2010; 140(3):1032-42. DOI: 10.1053/j.gastro.2010.11.036. View